Nomura Holdings’s Travere Therapeutics TVTX Stock Holding History

Nomura Holdings’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$514K	Buy	17,300 +9,800	+131%	+$293K	﹤0.01%	1355
2025 Q4	$287K	Buy	+7,500	New	+$244K	﹤0.01%	1683

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nomura Holdings's TVTX Position: Q1 2026 in Review

Nomura Holdings sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 27,241 shares — an estimated $814K sold.

Nomura Holdings first reported a position in TVTX in Q2 2019 and held it in 6 quarters. The position peaked at $2.38M in Q2 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Nomura Holdings reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
Nomura Holdings sold 27,241 Travere Therapeutics shares in Q1 2026, an estimated $814K.
Nomura Holdings first reported a position in Travere Therapeutics in Q2 2019 and held it in 6 quarters.
Nomura Holdings's Travere Therapeutics position peaked at $2.38M in Q2 2020.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.